A federal appeals court on Wednesday rejected a lawsuit by pharmaceutical industry representatives challenging the Medicare drug price negotiation program, ruling that drugmakers have no constitutional right to dictate prices paid by the federal program. The U.S. Court of Appeals for the Fifth Circuit upheld the program, which allows Medicare to negotiate prices for certain high-cost drugs, marking a significant legal victory for the Biden administration’s prescription drug cost reduction efforts.
The decision, handed down by a panel of judges on the Fifth Circuit, affirmed a lower court ruling and dismissed the argument from the Pharmaceutical Research and Manufacturers of America (PhRMA) that the program violates drugmakers' due process rights by forcing them to accept prices below market value. The court reasoned that participation in Medicare is voluntary and that drug companies are not entitled to a specific price when selling to the program.
"The drug manufacturers are not being compelled to sell their products to Medicare at a price they would prefer," the court wrote in its opinion. "The program is a lawful exercise of Congress's power to control spending and ensure fiscal responsibility in a major federal entitlement program."
The Medicare drug price negotiation program, a key provision of the Inflation Reduction Act of 2022, empowers the Centers for Medicare & Medicaid Services to negotiate prices for a select list of expensive drugs covering millions of beneficiaries. The first round of negotiations, covering drugs like Eliquis and Jardiance, is set to conclude this year, with lower prices expected to take effect in 2026.
PhRMA and other industry groups had argued that the program amounts to unconstitutional price controls, warning it would stifle innovation and limit patient access to new treatments. They have vowed to continue fighting the program through other legal avenues and legislative efforts.
Patient advocacy groups and consumer health organizations praised the ruling, calling it a victory for seniors who face high out-of-pocket costs. "This decision confirms that the government can and must act to make prescription drugs more affordable," said a spokesperson for AARP, which has supported the negotiation program.
The ruling is likely to face further appeals, possibly to the Supreme Court. Legal experts say the case could have broad implications for federal spending power and the regulation of prescription drug markets.
The decision comes as the first negotiated prices are expected to be announced later this year, potentially saving Medicare billions of dollars annually and easing financial burdens on beneficiaries.
Analysis
Why This Matters
- Direct savings for seniors: The program is expected to reduce out-of-pocket costs for millions of Medicare beneficiaries who rely on expensive drugs for chronic conditions like heart disease, diabetes, and cancer.
- Precedent for drug pricing reform: If upheld, the ruling strengthens the federal government's ability to negotiate drug prices, potentially leading to expansion to more drugs and even broader cost-control measures.
- Industry backlash and political stakes: Pharmaceutical companies will likely escalate legal and lobbying efforts, making this a key issue in upcoming elections and congressional debates over healthcare spending.
Background
The Medicare Part D prescription drug benefit, established in 2003, explicitly prohibited the government from negotiating drug prices, a concession to the pharmaceutical industry. Over the years, rising drug costs have become a major financial strain on seniors and the federal budget. The Inflation Reduction Act of 2022 broke this precedent by authorizing Medicare to negotiate prices for a limited set of drugs. The law targets drugs that are among the highest-spending for Medicare and have no generic competition. PhRMA filed its first lawsuit in 2023, arguing that the program violates the Fifth Amendment by taking property without just compensation. The Fifth Circuit's ruling is the latest in a series of court decisions that have largely upheld the program, though other challenges remain pending.
Key Perspectives
Biden Administration and CMS: The program is a centerpiece of the administration's effort to lower healthcare costs and is being implemented as planned. Officials argue it is a lawful and necessary step to curb unsustainable drug spending.
PhRMA and Drugmakers: They contend the program is an unconstitutional price control that undermines innovation and could lead to fewer new drugs. They warn that reduced profits will eventually harm patients by limiting research and development.
Patient Advocates and Consumer Groups: Groups like AARP and Families USA applaud the ruling as a victory for affordability. They say drug companies have long profited excessively at the expense of seniors and the taxpayers.
Legal Experts and Skeptics: Some note that while the program survived this challenge, other lawsuits could succeed on different grounds, such as specific procedural issues. They caution that the ultimate outcome may depend on a Supreme Court review, which could introduce uncertainty.
What to Watch
- Supreme Court appeal: Whether PhRMA petitions the Supreme Court and whether the justices agree to hear the case could determine the program's long-term viability.
- First negotiated price announcement: The release of initial price reductions later this year will test the program's actual impact on costs and may influence public and political support.
- Congressional actions: Pharmaceutical industry allies may push for legislation to amend or repeal the program, particularly if control of Congress shifts after the 2026 midterm elections.